Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Breast 5Tumor-Agnostic 4Gynecologic 3Gastrointestinal 3Sarcoma 2Genitourinary 2Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Osteosarcoma 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × ceralasertib × Sarcoma × Clear all
NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
63 enrolled
Sarcoma

Osteosarcoma

NCT04065269 2026-02-20

ATARI

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
174 enrolled
GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡